Ovid Therapeutics Inc. (OVID): Price and Financial Metrics
GET POWR RATINGS... FREE!
OVID POWR Grades
- Growth is the dimension where OVID ranks best; there it ranks ahead of 86.37% of US stocks.
- The strongest trend for OVID is in Growth, which has been heading up over the past 199 days.
- OVID ranks lowest in Sentiment; there it ranks in the 4th percentile.
OVID Stock Summary
- The ratio of debt to operating expenses for Ovid Therapeutics Inc is higher than it is for about just 0.32% of US stocks.
- With a price/sales ratio of 18.03, Ovid Therapeutics Inc has a higher such ratio than 89.27% of stocks in our set.
- Revenue growth over the past 12 months for Ovid Therapeutics Inc comes in at 82.49%, a number that bests 93.78% of the US stocks we're tracking.
- Stocks that are quantitatively similar to OVID, based on their financial statements, market capitalization, and price volatility, are GSIT, LPTX, KDMN, CERC, and ONCT.
- OVID's SEC filings can be seen here. And to visit Ovid Therapeutics Inc's official web site, go to www.ovidrx.com.
OVID Stock Price Chart Interactive Chart >
OVID Price/Volume Stats
|Current price||$3.48||52-week high||$9.40|
|Prev. close||$3.46||52-week low||$2.25|
|Day high||$3.53||Avg. volume||3,201,467|
|50-day MA||$3.83||Dividend yield||N/A|
|200-day MA||$4.58||Market Cap||235.91M|
Ovid Therapeutics Inc. (OVID) Company Bio
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company was founded in 2014 and is based in New York City, New York.
OVID Latest News Stream
|Loading, please wait...|
OVID Latest Social Stream
View Full OVID Social Stream
Latest OVID News From Around the Web
Below are the latest news stories about Ovid Therapeutics Inc that investors may wish to consider to help them evaluate OVID as an investment opportunity.
The odds of bankrupt HMNY stock getting acquired may be slim, but for these seven other Reddit penny stocks it's definitely a possibility.
Ovid Therapeutics Announces Appointment of Professor Robert S. Langer, Sc.D., as Chair of its Scientific Advisory Board
NEW YORK, April 20, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has appointed Professor Robert S. Langer, Sc.D., as Chairman of its Scientific Advisory Board. “We welcome Professor Robert Langer, who has joined Ovid as the new Chair of our Scientific Advisory Board,” said Amit Rakhit, M.D., MBA, President, Ovid Therapeutics. “Bob will help guide Ovid’s strategy to tackle opportunities and scientific questions underlying disorders in the brain. His perspective will be invaluable as we advance our pipeline of next-generation therapeutics. In addition, he will play a pivotal role as we expand our thought leadership on ...
Ovid Therapeutics (OVID) has slipped 3.2% postmarket after a downgrade to Neutral at Cantor Fitzgerald, pointing to decisions to discard development of approaches to Angelman syndrome and Fragile X syndrome. The company is refocusing on development of its early-stage pipeline, including OV882, a short hairpin RNA therapy targeting UBE3A gene...
Ovid Therapeutics Stops Gaboxadol Development Citing Limited Efficacy In Rare Neurological Conditions
Ovid Therapeutics Inc (NASDAQ: OVID ) has announced to discontinue the development of OV101 (gaboxadol), a delta (δ)-selective GABAA receptor agonist, in Angelman syndrome and Fragile X syndrome. The company says that while OV101 was well tolerated, with no significant safety signals observed, the company believes that efficacy outcomes observed in these trials do not support its further development. Now, the company … Full story available on Benzinga.com
Completed Soticlestat Agreement with Takeda Provides Significant Resources to Advance and Enrich OVID’s Pipeline, Including OV882 for Angelman Syndrome Company Reiterates Anticipated Quarterly Operating Expenses Guidance of Between $8 Million and $10 Million Beginning in 2Q 2021 NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced an update on its OV101 program and the prioritization of its resources to focus on the development of its robust early-stage pipeline, including OV882, a short hairpin RNA therapy targeting UBE3A gene expression in neurons, as a potential treatment for Angelman syndrome. As part of this...
OVID Price Returns